Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC)

Christina Fotopoulou 1,12✉, Andrea Rockall 1,2,3,12, Haonan Lu1, Philippa Lee2, Giacomo Avesani1,3,4, Luca Russo4, Federica Petta4, Beyhan Atasevenc, Kai-Uwe Waltering7, Jens Albrecht Koch7, William R. Crum3,8, Paula Cunnea 1, Florian Heitz 5,9, Philipp Harter5, Eric O. Aboagye3, Andreas du Bois5,13 and Sonia Prader5,10,11,13

© The Author(s) 2021

BACKGROUND: Predictive models based on radiomics features are novel, highly promising approaches for gynaecological oncology. Here, we wish to assess the prognostic value of the newly discovered Radiomic Prognostic Vector (RPV) in an independent cohort of high-grade serous ovarian cancer (HGSOC) patients, treated within a Centre of Excellence, thus avoiding any bias in treatment quality.

METHODS: RPV was calculated using standardised algorithms following segmentation of routine preoperative imaging of patients (n = 323) who underwent upfront debulking surgery (01/2011-07/2018). RPV was correlated with operability, survival and adjusted for well-established prognostic factors (age, postoperative residual disease, stage), and compared to previous validation models.

RESULTS: The distribution of low, medium and high RPV scores was 54.2% (n = 175), 33.4% (n = 108) and 12.4% (n = 40) across the cohort, respectively. High RPV scores independently associated with significantly worse progression-free survival (PFS) (HR = 1.69; 95% CI:1.06–2.71; P = 0.038), even after adjusting for stage, age, performance status and residual disease. Moreover, lower RPV was significantly associated with total macroscopic tumour clearance (OR = 2.02; 95% CI:1.56–2.62; P = 0.00647).

CONCLUSIONS: RPV was validated to independently identify those HGSOC patients who will not be operated tumour-free in an optimal setting, and those who will relapse early despite complete tumour clearance upfront. Further prospective, multicentre trials with a translational aspect are warranted for the incorporation of this radiomics approach into clinical routine.

British Journal of Cancer (2022) 126:1047–1054; https://doi.org/10.1038/s41416-021-01662-w

BACKGROUND

Surgical and systemic treatment of high-grade serous epithelial ovarian cancer (HGSOC) has experienced unprecedented advances over the last two decades. Through refinement of cytoreductive techniques, the introduction of novel targeted agents and the implementation of genetic and tumour profiling studies, our therapeutic strategies have evolved towards a maximal effort approach across multiple levels that has led to a significant improvement in patient survival [1]. Still, reliable prognostic and predictive biomarkers that would allow the development of more personalised treatment pathways for patients are lacking [2]. The concept of radiomics analysis is a promising novel approach in that direction. Radiomic algorithms based on high-dimensional quantitative features extracted from conventional imaging modalities have been demonstrated to represent a non-invasive platform to quantify tumour heterogeneity and determine prognostic signatures for operability and relapse [3–9].

It is known that despite obtaining total macroscopic tumour clearance at maximal effort upfront debulking surgery, ~25% of patients will relapse early, already in the first postoperative year [10–12]. In an effort to be able to identify those patients with less favourable outcomes, we have recently discovered a novel radiomic signature of tumour phenotype and prognosis, derived...
from the segmentation of conventional preoperative CT imaging [13]. Using machine-learning and radiomic methods, we derived a non-invasive summary-statistic of the primary ovarian tumour, based on four descriptors, named Radiomic Prognostic Vector (RPV), which reliably identified those patients who would relapse early and have a median overall survival of less than 2 years from initial diagnosis. This novel RPV biomarker was validated in two multicentre independent cohorts: the Hammersmith Hospital, Imperial College Healthcare NHS Trust London (HH), and patients from the Cancer Genome Atlas (TCGA) project [13]. In this study, we wished to evaluate the applicability of our novel radiomics biomarker in an independent cohort of patients, operated within an ESGO (European Society of Gynaecological Oncology) certified Ovarian Cancer Centre of Excellence, the Department of Gynaecologic Oncology Kliniken Essen-Mitte (KEM). To strengthen the basis for future clinical implementation, data were additionally correlated with our previous findings from the HH cohort.

METHODS
Patients’ selection and treatment modalities
Retrospective cohort study design with ethical approval for retrospective analysis of human data was obtained under the Hammersmith and Queen Charlotte’s & Chelsea Research Ethics Committee approval 05/Q0406/178 and the Klinik Essen-Mitte Research Ethics Committee approval and informed consent was waived. The study was performed in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All consecutive HGSOC patients who underwent primary debulking surgery in KEM between January 2011 and July 2018 were screened for the present analysis. Patients were eligible for inclusion if they were confirmed to have HGSOC histology and an evaluable portal venous CT through the primary ovarian tumour mass prior to undergoing upfront cytoreductive surgery, i.e. before any systemic chemotherapy. Any suspicious bulky visible lesions (≥1 cm) from the CT scan were included in the segmentation process. Patients were not eligible if no primary tumour mass was visible due to the initial absence of adnexal mass or due to surgical excision or if the patient has undergone preoperative chemotherapy (see consort diagram in Supplementary Fig. 1).

Patient demographics, surgical and tumour related data were retrieved from a prospectively populated database in the KEM centre; as opposed to the retrospective data retrieval from medical notes in the HH cohort, as described elsewhere [13]. Progression-free survival (PFS) and overall survival (OS) were defined as the time from the date of surgery to the date of first relapse or death, respectively. Staging was defined according to FIGO-criteria for ovarian epithelial carcinoma [14]. Since FIGO staging criteria changed during the observation time, FIGO stage was adapted to 2014 criteria and applied to patients diagnosed before then. Patients were divided into those with total macroscopic tumour clearance (tumour-free; TF) versus those with any macroscopic postoperative residual disease (i.e. >0 mm; non-tumour-free; NTF).

As in the RPV discovery study [13], all operations were performed within a maximal effort setting aiming to achieve total macroscopic tumour clearance as defined by the surgical quality assurance criteria of the ESGO [15] and AGO guidelines (https://www.ago-online.de/en/leitlinien-empfehlungen/leitlinien-empfehlungen/kommission-ovar). The surgical standards, approach and procedures followed at KEM have been extensively described previously [16–18]. All patients were to subsequently receive platinum-based combination chemotherapy, unless contraindications applied such as poor performance status. Maintenance regimens and availability of clinical trials differed between the KEM and the primary HH study setting, mainly due to funding and licensing differences between the European Medical Agency (EMA) and the UK National Institute for Health and Care Excellence (NICE UK).

Oncologic follow-up in KEM was performed according to the German follow-up recommendations, mainly symptom-guided and based on clinical and ultrasonographic examination in combination with CA-125 measurement in the majority of patients; initially 3-monthly for the first 3 years and then 6-monthly. A CT or MRI scan was performed if the above examinations revealed any pathology. Isolated CA-125 increase was not regarded as a recurrence. For the HH cohort, follow-up patterns for patient care were similar. Patients were routinely evaluated at the end of their treatment for evidence of disease recurrence. Clinical examination and CA-125 assessment (if the preoperative value was elevated) were performed every 3 months for the first 2 years and then 6-monthly. Even though a CT/MRI scan was ordered if the above examinations revealed any pathology, no routine ultrasonographic examinations were performed at follow-up in asymptomatic patients. As in KEM, an isolated CA-125 increase was not regarded as a recurrence.

Description of the radiomic signature and imaging segmentation
Radiomics quantifies mesoscopic tumour phenotype from anatomic or functional images by defining tumour spatial complexity, including first and higher-order statistics, fractal and shape features, generating disease features not appreciated by the naked eye [13]. The development of our radiomic signature, the Radiomic Prognostic Vector (RPV), is described elsewhere and we refer to that source for a more detailed description [13]. The radiomic image features included in the three groups: (1) shape and size features, relating to the shape of the tumour; (2) first-order statistics, quantifying tumour voxel intensity characteristics; (3) second-order statistics consisting of textural features which quantify different measures of three-dimensional intra-tumoural heterogeneity and (4) wavelet features calculating the features in Group 2 and 3 after performing wavelet decompositions of the original image using high-pass or low-pass filters from the coiflet 1 family of wavelets. All feature algorithms were implemented within MATLAB [13].

As patients were referred to the cancer centre from a network of cancer units, contrast-enhanced CT scans were acquired at multiple institutions using different manufacturers and different imaging protocols. All anonymised images and data were transferred electronically, and all evaluable primary ovarian tumour masses were segmented separately by trained radiology registrars (PL, FP and LR) using ITK snap (Version 3.2, 2015) and then all segmentations were checked in consensus with two experienced radiologists especially dedicated and trained in ovarian cancer imaging and who took part in the original study (GA and AR). Moreover, although the CT scans were performed by different radiology teams in the two centres for clinical care, the segmentation of scans and generation of the RPV scores in the KEM cohort was performed by the same team as the initial introductory study on the HH patients, to reduce possible bias.

As described previously, the entire primary adnexal mass volume (both cystic and solid components) was included in the analysis [13]. If both adnexa were involved, then both were included in the analysis, either as two separate segmentations or as a single segmentation if the mass was confluent. The segmentations only included tissue that was considered highly likely to be cancer by the expert reader. Areas of doubt on CT were not included in any segmentations. In summary, inclusion criteria related to the CT images were as follows: primary adnexal mass visible, portal venous phase CT through the adnexal mass, no previous surgical or medical treatment for ovarian cancer. Exclusion criteria related to images were: non-contrast or arterial phase CT with no portal venous phase, adnexal mass not included on CT, previous surgery for resection of an adnexal mass, neoadjuvant chemotherapy, the significant artefact for example from metal prostheses that precluded meaningful segmentation of adnexal mass. An outline of the study workflow is shown in Fig. 1a.

The software used was the in-house developed texture analysis package (TextLAB 2.0) developed in MATLAB 2015b (Mathworks Inc., Natick, Massachusetts, USA) [19].

Statistical analysis
R (https://www.R-project.org/) was used for statistical analysis. Kaplan–Meier analysis was performed using ‘ggkm’ function from ‘survival’ and ‘ggkm’ packages, with arguments ‘pval=1’, ‘table=TRUE’. RPV low, medium and high scores were defined as previously described [13]. Cox regression analysis was performed using ‘coxph’ function from ‘survival’ package.

We have chosen well-established and recognised clinical prognosticators of HGSOC [1, 10, 11] to be included as categorical variables in the univariate and multivariable regression to assess the prognostic value of our RPV model. These were: FIGO stage, age, postoperative residual disease, and ECOG status.

The first two principal components were tested in the unpaired t test to compare variations in radiomic data from KEM, HH and TCGA cohorts. ‘pcomp’ and ‘ggbiplot’ function from ‘stats’ and ‘ggbiplot’ packages were used to perform the principal component analysis (PCA). Radiomic data were centred and scaled before used as input. Two-sided, unpaired t tests...
RESULTS
Patient demographics, tumour characteristics and survival data
All patient- and surgery-related characteristics, as well as survival data for KEM (n = 523), are presented with the corresponding information from the primary discovery/validation study cohort from HH (n = 224) in Table 1 and consort diagram in Supplementary Fig. 1. Almost half of the patients were older than 60 years of age and the vast majority (92.3%) had advanced Stage III or IV disease. There were significant differences between the two centres, in that KEM had a significantly higher rate of Stage-IV patients, and ECOG status was not known in the majority of the HH patients. For almost one-third of the HH patients, no data were available for postoperative residual disease, mainly attributed to the retrospective data retrieval, therefore these patients were not included in the survival analysis specifically related to postoperative residual disease but were included in the overall survival studies. Approximately half of the patients had relapsed within the follow-up time of the present analysis. There was no difference in overall survival (OS) between the two centres for Stage III or IV patients, as well as PFS for Stage-IV patients. The PFS in Stage-III patients was significantly higher for the KEM cohort (P = 0.0312, log-rank test; Supplementary Fig. 2).

Prognostic value of RPV
Overall, the distribution of the KEM- patients to low, medium and high RPV scores was 54.2% (n = 175), 33.4% (n = 108) and 12.4% (n = 40), respectively (Table 1). Lower RPV was associated with higher rates of total macroscopic tumour clearance in the KEM cohort (OR = 2.02; 95% CI: 1.56–2.62, P = 0.00647). Patients with high RPV had a significantly worse PFS (median PFS = 18.10 months; IQR: 13.20–26.00 months) compared to those with medium or low RPV (median PFS = 25.90 months; IQR: 17.00–50.20, log-rank test P = 0.00452); the latter belonging to the most favourable patient subgroup (Fig. 1b). In order to assess RPV through its ability to predict survival or recurrence by specific landmark time points, we have compared patients’ outcome at 1, 2 and 3 years. Even though the 1-year OS and PFS rates were not significantly different between the different RPV groups (P = 0.306 and 0.509, respectively), patients with low/med RPV scores were 26% (P = 0.02) and 17% (P = 0.11) more likely to be free of progression at 2- and 3 years after surgery respectively, compared to patients with high RPV scores.

Patients with lower RPV who were tumour-free following upfront debulking exhibited a better PFS than patients with high RPV (P = 0.0172, log-rank test; Fig. 2a), or with any remaining residual disease following surgery (P < 0.0001, log-rank test;Fig. 2b).

Univariate analysis identified advanced FIGO stage (as a continuous variable), as well as the presence of any postoperative visible residual disease (versus only microscopic), ECOG and high RPV (versus medium/low), as significant factors for relapse. In multivariable analysis, three factors retained their significant impact on PFS: increasing FIGO stage (hazard ratio (HR) = 1.8; 95% CI: 1.32–2.45; P = 0.000191), any postoperative residual disease (HR = 3.00; 95% CI: 2.09–4.32; P = 3.16 × 10^-3) and high RPV versus medium/low (HR = 1.69; 95%CI: 1.06–2.71; P = 0.0279); while age (HR = 0.88; 95% CI: 0.62–1.24; P = 0.463) and ECOG status (HR = 1.18; 95% CI: 0.722–1.94; P = 0.506) did not retain significance in the multivariable analysis (Table 2). No prognostic value of the RPV could be identified for overall survival neither in the entire KEM patients’ cohort nor the tumour-free patient sub-cohort. The known risk factors of FIGO stage and postoperative residual disease [1, 10, 11], were confirmed as significantly affecting overall survival, adding to the validity of our data (Supplementary Table 1). We further examined whether there was any significant association between BRCA status and RPV in the KEM cohort. Information on BRCA mutational status was available for over half of the patients (n = 172), however consistent with the RPV discovery study [13], no association was observed between RPV and BRCA status (Supplementary Fig. 3).

Comparison of radiomic features between the two centres
As shown in Fig. 3a, differences exist between the RPV features between the two cohorts which may be attributed to the higher rate of Stage-IV patients in the KEM population. A higher number of patients classified as RPV-high were present in the KEM cohort in comparison to the HH (P = 0.00253; Fisher’s exact test) and TCGA (P = 0.025; Fisher’s exact test) cohorts. As our previous study showed that RPV is negatively correlated with tumour volume [13], we compared the segmented tumour size among the three cohorts TCGA, HH and KEM (Fig. 3b). Our findings demonstrate that the size of the segmented tumours from the KEM cohort was significantly smaller than those of the HH (P = 2.102e-06; t test) or TCGA (P = 0.00943; t test) cohorts, additionally probably contributing to the significantly higher number of KEM patients with RPV-high features.

We performed a principal component analysis to compare the radiomic data structure between KEM, HH and TCGA. As demonstrated in Fig. 3c, the radiomics profile from HH and TCGA
cohorts are closely clustered together ($P > 0.05$, t test) and shifted from the radiomics profile from the KEM cohort ($P < 0.0001$, t test), suggesting a fundamental difference in the radiomic data structure. This may well be attributed to the differences in tumour stage and size between the two cohorts, but we cannot be certain about the exact reasons nor the magnitude of each factor. This would warrant exploring in any future prospective evaluation for RPV.

**DISCUSSION**

Our data confirm the promising value of radiomics analysis in patients with HGSOC and additionally enriches the landscape of evidence around radiomic-based approaches in gynaecological cancer overall. We have confirmed the independent prognostic value of the radiomic signature RPV in regards to postoperative residual disease and PFS in HGSOC patients treated within a specialised setting. We demonstrated that those patients with high RPV scores had a significantly worse PFS even after adjustment for other well-established prognostic factors such as FIGO stage, age, performance status and postoperative residual disease. Interestingly, RPV scores did not appear to be influenced by the BRCA status of the patients, confirming our discovery study reports.

By identifying through a robust algorithm, such as the RPV signature, those patients who will relapse early despite our best therapeutic efforts, i.e. primary debulking surgery consolidated by conventional cytotoxic chemotherapy, we can spare them from the unnecessary toxicity that these treatments are potentially associated with, and direct them towards other avenues such as neoadjuvant chemotherapy, early introduction of novel targeted agents, or even omission of cytotoxic chemotherapy and introduction of alternative treatment strategies such as adjuvant drug conjugates or approaches based on molecular profiling, patient-derived organoid, explant or xenograft models.

The fact that the RPV biomarker can be readily calculated by a standardised mathematical model through a segmentation process of routine preoperative patient imaging, automatically translates its potential straightforward implementation into surgical practice for the preoperative stratification of patients towards a more individualised surgical care. Also, the fact that the quality of the preoperative imaging was not standardised and

| Characteristics | KEM ($n = 323$) | HH ($n = 224$) | $P$ value |
|-----------------|------------------|----------------|-----------|
| Age years (%)   |                  |                |           |
| <60             | 160 (49.5)       | 97 (43.4)      | ns        |
| >60             | 163 (50.0)       | 127 (56.7)     |           |
| FIGO stage (%)  |                  |                |           |
| I               | 6 (1.9)          | 9 (4)          | <0.0001   |
| II              | 14 (4.3)         | 16 (7.1)       |           |
| III             | 132 (40.9)       | 135 (60.3)     |           |
| IV              | 166 (51.4)       | 61 (27.2)      |           |
| Unknown         | 5 (1.5)          | 3 (1.3)        |           |
| ECOG (%)        |                  |                |           |
| 0               | 297              | 11             | <0.0001   |
| 1               | 20               | 31             |           |
| 2               | 5                | 18             |           |
| 3               | 1                | 2              |           |
| Unknown         | –                | 162            |           |
| BRCA status     |                  |                |           |
| BRCA1/2 mut     | 99               | –              |           |
| Wild-type       | 73               | –              |           |
| Unknown         | 151              | 224            |           |
| Residual disease (%) |            |                |           |
| Tumour-free     | 196 (60.7)       | 106 (47.3)     | ns        |
| Non-tumour-free | 122 (37.8)       | 47 (21)        |           |
| Unknown         | 5 (1.5)          | 71 (31.7)      |           |
| RPV             |                  |                |           |
| Low             | 175              | 147            | 0.00253   |
| Medium          | 108              | 66             |           |
| High            | 40               | 11             |           |
| Follow-up (months; median IQR) | 34.5 (13.1–54.4) | 49.3 (16.5–71.8) | ns |
| PFS (months; median IQR) | All 23.9 (16.2–49.7) | 21.1 (11.7–50.9) | ns |
|                   | Stage III 26.60 (17.50–49.80) | 19.41 (12.36–41.28) | 0.0312 |
|                   | Stage IV 21.20 (13.30–31.60) | 13.54 (8.89–37.25) | ns |
| OS (months; median IQR) | All 53.2 (24.7–NR) | 51.8 (25.5–NR) | ns |
|                   | Stage III 59.10 (27.20–NR) | 53.15 (25.97–85.08) | ns |
|                   | Stage IV 37.40 (19.70–57.50) | 33.51 (19.08–53.05) | ns |
| Relapsed (%)     |                  |                |           |
| No              | 167 (51.7)       | 96 (42.9)      | ns        |
| Yes             | 156 (48.3)       | 108 (48.2)     |           |
| Unknown         | –                | 20 (8.9)       |           |
| Deceased (%)    |                  |                |           |
| No              | 211 (65.3)       | 133 (59.4)     | ns        |
| Yes             | 112 (34.7)       | 90 (40.2)      |           |
| Unknown         | –                | 1 (0.4)        |           |
able to do so for more longer-term outcomes. Nevertheless, prediction of operability was not the aim of our work. The aim of our work was to identify those patients, who despite the best and maximal therapeutic effort, did not perform well, therefore we can use the RPV to identify those and spare them unnecessary iatrogenic morbidity.

Our results are in accordance with other studies that have similarly identified radiomics nomograms as an effective tool to predict PFS for patients with advanced HGSOC [3–9]. Meier et al. had similarly demonstrated that a higher inter-site cluster variance, as derived from computed tomography by measuring the inter-site texture heterogeneity parameters, was associated with lower PFS and OS in HGSOC patients [20]. Wang et al. were the first to evaluate the radiomics approach in even more advanced imaging such as PET [8]. They have demonstrated that PET-based radiomic signatures can improve diagnostic accuracy and provide complementary prognostic information compared with the use of clinical factors alone or even combined with radiomic signatures derived from conventional CT, to predict PFS for patients with advanced HGSOC.

To bring it even a step beyond mere prognosticators, Martin-Gonzalez et al. have recently described how current challenges in the treatment of ovarian cancer might be overcome by integrating quantitative radiomic features with the analysis of paired genomic profiles, a combined approach called radiogenomics, to generate virtual biopsies [5]. The association of radiomic signatures with paired molecular profiles were shown to be able to monitor varied between the different centres without having a deleterious effect on the ability to adequately perform the necessary segmentation, the RPV biomarker is likely to be highly generalisable without more specialised training required for its use. This would imply its possible straightforward broader application in different healthcare settings following full validation within a prospective, multicentre trial design.

When assessing the ability of RPV to predict survival or recurrence by specific landmark time points, we could demonstrate, that even though the 1-year OS and PFS rates were not significantly different between the different RPV groups, patients with low/med RPV scores were 26 and 17% more likely to be progression-free at 2- and 3 years after surgery, respectively, in comparison to patients with high RPV. This clearly indicates that even though RPV does not appear to be suited to identify those patients with the highly unfavourable short-term outcome, it is able to do so for more longer-term outcomes.

We have demonstrated a significant association between lower RPV and higher rates of total macroscopic tumour clearance. Nevertheless, prediction of operability was not the aim of our present work. The patients that were included in the present analysis are all operated, so a priori identified from the general cohort as optimal surgical candidates. This means that predictive models of operability were already applied. In addition to that, as both centres were centres of excellence, the rate of patients who had optimal debulking was very high due to accurate patient selection for surgery, resulting in fewer non-tumour-free operated patients. The aim of our work was to identify those patients, who despite the best and maximal therapeutic effort, did not perform well, therefore we can use the RPV to identify those and spare them unnecessary iatrogenic morbidity.

| Feature                          | Univariate HR (95% CI) | P value   | Multivariable HR (95% CI) | P value |
|----------------------------------|------------------------|-----------|---------------------------|---------|
| RPV (low/med vs high)            | 1.94 (1.24–3.04)       | 0.00383   | 1.69 (1.06–2.71)          | 0.0279  |
| FIGO stage*                      | 2.14 (1.59–2.87)       | 4.18 × 10^{-7} | 1.8 (1.32–2.45)          | 0.000191|
| Residual disease (none vs any)   | 3.55 (2.54–4.96)       | 1.22 × 10^{-13}  | 3.00 (2.09–4.32)         | 3.16 × 10^{-9}|
| Age (<60 y vs >60 y)             | 1.32 (0.964–1.81)      | 0.0837    | 0.88 (0.62–1.24)          | 0.463   |
| ECOG*                            | 1.75 (1.12–2.74)       | 0.0147    | 1.18 (0.722–1.94)         | 0.506   |

*As continuous variable. Bold values indicate statistical significance.

Fig. 2 RPV is associated with PFS in patients with postoperative tumour-free status. a Kaplan–Meier analysis showing the association between RPV and PFS in the subgroup of patients without postoperative residual disease. b Kaplan–Meier analysis showing the association between RPV and postoperative residual disease with PFS in the entire KEM cohort. TF postoperative tumour-free, NTF non-postoperative tumour-free. RPV low and medium subgroups are combined to compare with RPV-high group. P values are given by log-rank test.

Table 2. Cox regression analysis for relapse (KEM cohort).
spatiotemporal changes in the heterogeneity of ovarian tumours. The team demonstrated that linking radiomics and biological signatures could potentially improve the clinical management of such a challenging disease by monitoring tumours during the course of therapy and offering additional information for clinical decision making [5]. Our initial RPV study had included integration of parallel genetic, transcriptomic and proteomic profiling of tumours to decipher a biological interpretation of the RPV biomarker, showing activation of stromal phenotype and DNA damage response pathways in RPV-stratified tumours [13].

Nevertheless, despite the encouraging data we were able to generate with regards to the prognostic significance of RPV for OS in the HH and TCGA data, we were unable to validate the RPV for OS in the KEM cohort, raising a question regarding its impact on the prediction of overall clinical and surgical outcome of HGSOCC patients. Previously, we have been able to demonstrate even within a multivariable Cox regression model including age, stage and postoperative residual disease, that RPV remained significantly and continuously associated with OS in the TCGA (HR: 4.87, 95% CI: 1.67–14.2, P = 0.00380) and the HH validation dataset (HR: 7.36, 95% CI: 1.29–41.9, P = 0.0245) [13]. These initial data were highly encouraging implying that the addition of RPV would improve the value of the already well-established clinical and surgical prognostic factors, especially since the RPV appeared to carry the strongest impact. The fact that we did not validate this impact now on a larger patient cohort of maximally operated patients generates the dilemma of whether to attempt to repeat our analysis within a prospective trials design or whether to re-evaluate the impact of RPV as a potentially valuable biomarker for overall survival.

We can only hypothesise about the altered impact of the RPV in the different patient cohorts and the lack of reproducibility of its prognostic value regarding OS as opposed to PFS. Since debulking status, stage, age and survival data in the entire cohort were not significantly different between the KEM and HH datasets; the lack of impact of RPV on the OS of the KEM patients cannot be attributed to a different approach in patient selection for surgery between the two centres nor to a presumed superior surgical quality of one centre over the other that would render weak prognostic biomarkers as invaluable within a high-quality treatment setting. The main clinically relevant difference between the two patient cohorts may have been the access to post-chemotherapy maintenance treatment regimens such as anti-angiogenetic agents, attributed to the highly significant licensing and funding between EMA and NICE. All Stage III and IV KEM ovarian cancer patients had access to postoperative bevacizumab, as opposed to only Stage IV and non-tumour-free operated Stage-III patients in the HH cohort, outside of clinical trials. As we know that in tumour-free operated Stage-III patients, the addition of bevacizumab has a significant impact only on PFS and not OS [21–23], this may be one of the main reasons for a better PFS in the Stage-III KEM cohort compared to HH.

Still, the aim of this study was not to compare centres and patients’ survival between two different centres, but to evaluate whether the value of RPV could be validated in a second independent centre. For that reason, the data neither were combined in the analysis nor did we assess the value of the factor “centre” as prognosticator.

Various studies have demonstrated the impact of stroma characteristics on the benefit derived from antiangiogenetic treatment which may confound our OS analysis [24–26]. Colon cancer studies for example exploring the independent prognostic value of the tumour–stroma ratio [25, 26] suggest a significantly shorter PFS and OS in stroma-low tumours with the addition of bevacizumab to intravenous oxaliplatin-based chemotherapy, contrary to stroma-high tumours, where a beneficial trend was observed [26]. In high-risk advanced-stage colon cancer, data have shown that even though the stromal organisation itself does not serve as an independent prognostic or predictive parameter; it appears that the combined parameters of stromal organisation and tumour–stroma ratio allow for the identification of those patients who will especially benefit from the addition of bevacizumab to the platinum-based chemotherapy [25]. Therefore, as we know that stromal phenotype and DNA damage response pathways are activated in RPV-stratified tumours [13], it is possible that the higher use of bevacizumab in the KEM–cohort invalidates the OS relationship with a stroma-related prognostic marker such as RPV.

The cystic part of the tumour was not incorporated in the initial development model of the RPV and was therefore equally not extra addressed here. However, the volume/voxel was shown to be correlated with many radiomic features including RPV in our previous study [13], while the prognostic power of RPV was independent of volume/voxel. The use of LASSO method during the development of RPV removed many highly correlated radiomic features, including those features that were all highly correlated with volume/voxel. A future study with a prospective design and a translational aspect may further elucidate these
complex interactions of stromal components, antiangiogenic agents and tumour size and thus establish the true predictive and prognostic value of RPV on OS.

A significant limitation of our study is the lack of correlation of the radiomics features of the KEM cohort with the equivalent biological characteristics of the tumours, as previously performed for the HH and TCGA cohorts due to the lack of histological evaluation of the KEM- specimens [13]. While in the discovery study, an associated molecular analysis of the RPV was possible due to routine banking of tumour tissues post-surgery, it is difficult to obtain further independent large patient cohort retrospective datasets with the same surgical standards with available tissue in sufficient numbers. To address this, we have commenced a prospective collection of CT scans, tumour samples and data in the HH-centre to perform a complete validation of the RPV with molecular analysis, and are developing prospective collaborations for a multicentre translational study. A future prospective study with a translational aspect of a parallel tissue collection to examine differences in tumour cellularity and stroma, fibronectin levels in RPV-high versus low tumours, coupled with targeted multi-omics profiling, will shed more light into understanding the biological background of our findings. Our aim is to determine whether and to what degree and context, stromal content, tumour cellularity, proliferation index, and homologous recombination and DNA damage response pathways, play a role in the biological behaviour of low/medium vs high RPV tumours [27–29].

In conclusion, in this study we demonstrate that patients with high RPV are associated with a 66% probability of a worse PFS regardless of the postoperative residual disease, age, performance status and stage. Although the impact of RPV did not validate for OS, RPV may be deemed valuable, even if only accurate for the prediction of relapse, to direct those patients with a much less favourable profile to alternative or modified treatment strategies. Key tasks towards future clinical use would include validation of the RPV in a large prospective cohort across a multicentre setting that could set the basis for a randomised trial design. Furthermore, we wish to develop a platform for the reliable automation or semi-automation of the segmentation process, which would be a significant advance towards the broader implementation of the RPV algorithm as a biomarker into routine clinical procedures. This would be a step towards a more individualised surgical stratification of patients.

DATA AVAILABILITY
RPV data and clinical annotations will be available upon publication.

REFERENCES
1. Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:668–79.
2. Gonzalez Bosquet J, Devor EJ, Newston AM, Smith BJ, Bender DP, Goodheart MJ, et al. Creation and validation of models to predict response to primary treatment in serous ovarian cancer. Sci Rep. 2021;11:5957.
3. Beer L, Sahin H, Bateman NW, Blizic I, Vargas HA, Veeraraghavan H, et al. Integration of proteomics with CT-based qualitative and radiomic features in high-grade serous ovarian cancer patients: an exploratory analysis. Eur Radiol. 2020;30:4306–16.
4. Li H, Zhang R, Li B, Xia W, Chen X, Zhang J, et al. Noninvasive prediction of residual disease for advanced high-grade serous ovarian carcinoma by MRI-based radiomic-clinical nomogram. Eur Radiol. 2021;31:7855–64.
5. Martin-Gonzalez P, Crispin-Ortuzar M, Rundo L, Delgado-Ortiz M, Reinus M, Beer L, et al. Integrative radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer. Insights Imaging. 2020;11:94.
6. Rizzo S, Botta F, Raimondi S, Origi D, Buscarino V, Colanetti A, et al. Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months. Eur Radiol. 2018;28:8489–59.
7. Vargas HA, Veeraraghavan H, Micco M, Nougarret S, Lakhman Y, Meier AA, et al. A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. Eur Radiol. 2017;27:3991–4001.
8. Wang X, Lu Z. Radiomics analysis of PET and CT components of [18F]-FDG PET/CT imaging for prediction of progression-free survival in advanced high-grade serous ovarian cancer. Front Oncol. 2021;11:638124.
9. Wei W, Liu Z, Rong Y, Zou B, Bai Y, Wei W, et al. A computed tomography-based radiomic prognostic marker of advanced high-grade serous ovarian cancer recurrence: a multicenter study. Front Oncol. 2019;9:255.
10. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studien- gruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115:1234–44.
11. Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N. Engl J Med. 2019;380:322–32.
12. Lu H, Cunnea P, Nixon K, Rinne N, Abboagye EO, Fotopoulou C. Discovery of a biomarker candidate for surgical stratification in high-grade serous ovarian cancer. Br J Cancer. 2021;124:1286–93.
13. Lu H, Arshad M, Thornton A, Avesani G, Cunnea P, Curry E, et al. A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer. Nat Commun. 2019;10:764.
14. Prat J. Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1–5.
15. Fotopoulou C, Concin N, Planchamp F, Morice P, Vergote I, du Bois A, et al. Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. Int J Gynecol Cancer. 2020;30:436–40.
16. Harter P, Mualllem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R, et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecol Oncol. 2011;121:615–9.
17. Heitz F, Harter P, Alesina PF, Walz MK, Lorenz D, Groebe H, et al. Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery. Gynecol Oncol. 2016;141:264–70.
18. Kommoss S, Rochon J, Harter P, Heitz F, Grabowski JP, Ewald-Riegler N, et al. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer. Ann Surg Oncol. 2010;17:279–86.
19. Arshad MA, Thornton A, Lu H, Tam H, Wallitt K, Rodgers N, et al. Discovery of pretherapy 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography-based radiomics classifiers of survival outcome in non-small-cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2019;46:455–66.
20. Meier A, Veeraraghavan H, Nougarret S, Lakhman Y, Sosa R, Soslow RA, et al. Association between CT-texture-derived tumour heterogeneity, outcomes, and BRCA mutation status in patients with high-grade serous ovarian cancer. Abdom Radiol. 2019;44:2040–7.
21. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl J Med. 2011;365:2473–83.
22. Monk BJ, Dalton H, Farley JH, Chase DM, Benjamin I. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. Crit Rev Oncol Hematol. 2013;86:161–75.
23. Perren TJ, Swart AM, Pister J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2012;366:1125–35.
24. Gyorkey P, Gepts E, Huepbacher S, Bury J, De Boeck J, Langerack B, et al. Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery. Gynecol Oncol. 2016;141:264–70.
25. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl J Med. 2011;365:2473–83.
26. Monk BJ, Dalton H, Farley JH, Chase DM, Benjamin I. Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer. Crit Rev Oncol Hematol. 2013;86:161–75.
27. Perren TJ, Swart AM, Pister J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl J Med. 2011;365:2484–96.
28. Kassuwn W, Klein O, Darb-Esfahani S, Lammert H, Handzik S, Taube ET, et al. Classification of molecular subtypes of high-grade serous ovarian cancer by MALDI-imaging. Cancers. 2021;13:1512.
29. Zinzi S, van der Wilk P, Gelderblom H, Dekker T, Manco C, Kialainen A, et al. Stromal organization as predictive biomarker for the treatment of colon cancer with adjuvant bevacizumab; a post-hoc analysis of the AVANT trial. Cell Oncol. 2019;42:717–25.
30. Zinzi SM, van Pelt GW, Gelderblom HJ, Manco C, Putter H, Tollenaar RA, et al. Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer. Br J Cancer. 2018;119:164–9.
31. Chen JL, Espinosa I, Lin AY, Liao OY, van de Rijn M, West RB. Stromal responses of low/medium vs high RPV tumours [27–29].
28. Cook GJ, Yip C, Siddique M, Goh V, Chicklore S, Roy A, et al. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? J Nucl Med. 2013;54:19–26.

29. Kristensen VN, Lingjaerde OC, Russnes HG, Vollan HK, Frigessi A, Borresen-Dale AL. Principles and methods of integrative genomic analyses in cancer. Nat Rev Cancer. 2014;14:299–313.

ACKNOWLEDGEMENTS

The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. CF and PC acknowledge funding from Imperial Health Charity Imperial Centre and Imperial College London Tissue Bank. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

AUTHOR CONTRIBUTIONS

CF, AR, HL and EOA conceived the present study, AR, HL, WRC, and EOA developed the signature and performed the computations. HL performed the statistical analysis. PL, GA, LR and FP performed the segmentations. BA, K-UW, JAK, FH, PH, AB and SP provided the patient’s data. CF wrote the manuscript with support from PC and all the co-authors. All co-authors contributed to the interpretation of the data and approved the final version of the manuscript.

FUNDING

This article is independent research funded by the National Institute for Health Research (NIHR), Imperial Biomedical Research Centre (BRC), the Imperial College Experimental Cancer Medicine Centre (ECMC), with infrastructure support from CRUK Imperial Centre and Imperial College London Tissue Bank. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. CF and PC acknowledge funding from Imperial Health Charity (Ovarian Fund).

COMPETING INTERESTS

The authors declare no competing interests for this study. CF received honoraria from Ethicon, GSK, Astra Zeneca/MSD, Tesaro, Clovis, Sequana and Roche, outside of the submitted work. BA reports personal fees and non-financial support from Roche and Tesaro/GSK; personal fees from Astra Zeneca, Clovis, Celgene; MSD and Amgen; and non-financial support from PharmaMar, outside of the submitted work. PH reports travel support for an educational lecture from Guerbet Laboratories, outside of the submitted work. FH reports personal fees and non-financial support from Astra Zeneca, Roche, Tesaro, GSK and Clovis; non-financial support from NewOncoology, personal fees from NovoCure and PharmaMar, outside of the submitted work. ADB reports honoraria/expenses from Roche, Astra Zeneca, GSK/Tesaro, Clove, BIOCAD, Zodiac and Amgen, and consulting/advisory board for Roche, Astra Zeneca, GSK/ Tesaro, Clovis, Pfizer, BIOCAD, Genmab/Seattle Genetics, MSF and Amgen, outside of the submitted work. PH reports grants and personal fees from Astra Zeneca, Roche, Clovis, Immunogen and GSK; personal fees from Sotio, Stryker, Zai Lab, and MSD; grants from Public funding (EU, DKH and DFG); and grants from Boehringer Ingelheim, Medac, and Genmab; outside of the submitted work. The remaining authors declare no competing interests.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Retrospective cohort study design with ethical approval for retrospective analysis of human data was obtained under the Hammersmith and Queen Charlotte’s & Chelsea Research Ethics Committee approval 05/Q0406/178 and the Klinikum Essen-Mitte Research Ethics Committee approval and informed consent was waived. The study was performed in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

CONSENT TO PUBLISH

This manuscript does not contain any individual patient data.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41416-021-01662-w.

Correspondence and requests for materials should be addressed to Christina Fotopoulou.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021